Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sawai: Sales Up 18% with Good Sales of New Products
December 1, 2008
- Medical Fee System Needs Reform to Deal with High-Cost Drugs: Dr Ishikawa
December 1, 2008
- Taiyo Yakuhin: Sales Up 11.9%
December 1, 2008
- GL on Proper Use of Psychotropics in the Elderly Expected by 2010
December 1, 2008
- Towa: Sales Up 12.8% due to Expansion of Sales to Pharmacies
December 1, 2008
- Standard Regimens for Colon Cancer Used in 56% of Cases
December 1, 2008
- Actavis ASKA Aims at Becoming Leading Generic House in Japan
December 1, 2008
- MEDICAL DEVICE NEWS IN BRIEF
December 1, 2008
- Greater Efforts Needed to Promote Use of Generics: Chuikyo
December 1, 2008
- CMIC Aims at Entry into Western Market to Become a Global CRO
December 1, 2008
- Irbesartan Fails to Improve Outcome of Heart Failure Patients with Preserved LVEF
December 1, 2008
- TOPICS／Number of MRs Decreases for First Time in 2007
December 1, 2008
- Subject Enrollment to a PIII Trial of AMG706 Stopped
December 1, 2008
- Combined Sales of TSE 1st Section-Listed 22 Pharmas Up 3.9%
December 1, 2008
- Standard Forms Adopted by Only 70% of Med Institutions Participating in Clinical Trials
December 1, 2008
- VITAL-NET, KSK to Merge to Create 5th Largest Drug Wholesaler
December 1, 2008
- R&D NEWS IN BRIEF
December 1, 2008
- Nippon Shinyaku: Sales Up 14.1% Due to Licensing of NS-304
November 24, 2008
- REGULATORY NEWS IN BRIEF
November 24, 2008
- Seikagaku: Good Domestic Sales Fail to Make Up for Decreases in Exports
November 24, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…